-
2
-
-
84868131614
-
Randomized, controlled study of once daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes
-
Bergenstal RM, Rosenstock J, Arakaki RF, Prince MJ, Qu Y, Sinha VP, Howey DC, Jacober SJA. Randomized, controlled study of once daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012; 35:2140-2147.
-
(2012)
Diabetes Care
, vol.35
, pp. 2140-2147
-
-
Bergenstal, R.M.1
Rosenstock, J.2
Arakaki, R.F.3
Prince, M.J.4
Qu, Y.5
Sinha, V.P.6
Howey, D.C.7
Jacober, S.J.A.8
-
3
-
-
84869842163
-
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
-
On behalf of the NN1250-3579 (BEGIN Once Long) trial investigators
-
Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, Endahl L, Mathieu C. On behalf of the NN1250-3579 (BEGIN Once Long) trial investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012; 35:2464-2471.
-
(2012)
Diabetes Care
, vol.35
, pp. 2464-2471
-
-
Zinman, B.1
Philis-Tsimikas, A.2
Cariou, B.3
Handelsman, Y.4
Rodbard, H.W.5
Johansen, T.6
Endahl, L.7
Mathieu, C.8
-
4
-
-
84921667031
-
-
Guideline on adjustment for baseline covariates (draft) (accessed 23 February 2014)
-
The Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency. Guideline on adjustment for baseline covariates (draft). Available at: http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2013/06/WC500144946.pdf (accessed 23 February 2014).
-
The Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency
-
-
-
5
-
-
84880044149
-
Comparison of negative binomial regression models in analyzing hypoglycemic events
-
Luo J, Qu Y. Comparison of negative binomial regression models in analyzing hypoglycemic events. Pharmaceutical Statistics 2013; 12:233-242.
-
(2013)
Pharmaceutical Statistics
, vol.12
, pp. 233-242
-
-
Luo, J.1
Qu, Y.2
-
6
-
-
84882273956
-
The effect of adjusting for baseline hypoglycemia when analyzing hypoglycemia data: A systematic analysis of 15 diabetes clinical trials
-
Luo J, Jacober SJ, Prince MJ, Carey MA, Qu Y. The effect of adjusting for baseline hypoglycemia when analyzing hypoglycemia data: a systematic analysis of 15 diabetes clinical trials. Diabetes Technology and Therapeutics 2013; 15:654-661.
-
(2013)
Diabetes Technology and Therapeutics
, vol.15
, pp. 654-661
-
-
Luo, J.1
Jacober, S.J.2
Prince, M.J.3
Carey, M.A.4
Qu, Y.5
-
7
-
-
84921647112
-
-
SAS Institute, Inc. SAS/STAT 9.2 User's Guide. SAS Institute, Inc., Cary: NC, 2009
-
SAS Institute. Inc. SAS/STAT 9.2 User's Guide. SAS Institute, Inc., Cary: NC, 2009.
-
-
-
-
8
-
-
84904129897
-
-
(accessed 15 November 2012)
-
Lenth RV. Using the lsmeans Package. Available at: http://cran. r-project.org/web/packages/lsmeans/vignettes/using-lsmeans.pdf (accessed 15 November 2012).
-
Using the Lsmeans Package
-
-
Lenth, R.V.1
-
10
-
-
38149073314
-
Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: Prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy
-
Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008; 31:20-25.
-
(2008)
Diabetes Care
, vol.31
, pp. 20-25
-
-
Rosenstock, J.1
Ahmann, A.J.2
Colon, G.3
Scism-Bacon, J.4
Jiang, H.5
Martin, S.6
|